东吴证券给予迈威生物买入评级，IL-11单抗全球领先，战略布局抗衰老及病理性瘢痕等

Group 1 - Dongwu Securities issued a report on September 6, giving a "buy" rating to Maiwei Biotech (688062.SH, latest price: 58.22 yuan) [1] - The rating is primarily based on the global advancement of 9MW3811, an IL-11 monoclonal antibody independently developed by Maiwei Biotech, which has attracted attention from Silicon Valley giants [1] - The anti-aging mechanism of 9MW3811 is well-defined, with potential for future expansion into pathological scar indications [1] - The company has multiple promising pipelines that are expected to yield significant results [1]